# Fidocure

> Precision oncology platform matching canine cancer to targeted therapies via genomic testing.

## Why it is interesting

FidoCure brings human-grade cancer genomics to veterinary oncology — Lerer Hippeau joined a16z in seed and Series A rounds.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Seed (Jan 2019): $5M led by a16z Bio (/fund/andreessen-horowitz); Lerer Hippeau (/fund/lerer-hippeau), Y Combinator participated (TechCrunch)
- Series A (Oct 2020): $10M led by Polaris; a16z and Lerer Hippeau re-upped (PR Newswire)
- Product: genomic testing to match canine cancer to targeted therapies

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/lerer-hippeau

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/fidocure